ReviewBiology2026
Repositioning of Fluoroquinolones: A New Approach in Antitumor Therapy.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Fluoroquinolones are known for their antibacterial properties, but recent research has revealed their potential to inhibit the growth and proliferation of cancer cells. Thus, this study aimed to emphasize the repositioning and potential of fluoroquinolones as possible therapeutic tools in the fight against cancer, opening up new perspectives for the field of oncology. Thus, this paper consists of a descriptive literature review of recent studies published between 2013 and 2023 on the use of fluoroquinolones in anticancer therapy. The results indicate that fluoroquinolones can interfere with the cell cycle, induce apoptosis and oxidative stress, and impact factors associated with tumorigenesis, such as the transcription of ectopic expression of SNAI1 for epithelial-mesenchymal transition. In addition, studies show that combining fluoroquinolones with other antineoplastic agents can increase their efficacy, and the possibility of encapsulating these drugs in controlled-release systems is also emerging as a promising antitumor strategy. In conclusion, repositioning fluoroquinolones in antitumor therapy presents an expanding field of research, offering new perspectives for cancer treatment. However, more studies are needed to fully elucidate their potential and establish effective clinical use protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.